James Patrick Kelly - 12 Sep 2023 Form 4 Insider Report for NOVAVAX INC (NVAX)

Role
EVP, CFO and Treasurer
Signature
/s/ Mark J. Casey, Attorney-in-Fact
Issuer symbol
NVAX
Transactions as of
12 Sep 2023
Net transactions value
-$33,127
Form type
4
Filing time
11 Mar 2024, 21:39:24 UTC
Previous filing
18 Aug 2023
Next filing
26 Mar 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NVAX Common Stock Options Exercise +12,224 +267% 16,808 07 Mar 2024 Direct F1
transaction NVAX Common Stock Tax liability $33,127 -5,905 -35% $5.61 10,903 07 Mar 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NVAX Restricted Stock Units Award $0 -35,000 -50% $0.000000 35,000 12 Sep 2023 Common Stock 35,000 Direct F1, F2
transaction NVAX Restricted Stock Units Options Exercise $0 -12,224 -33% $0.000000 24,446 07 Mar 2024 Common Stock 12,224 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock.
F2 The RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, will vest in full as of December 31, 2024, subject to continued employment through such vesting date.
F3 The RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested or will vest with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of the March 7, 2023 grant date, in each case subject to continued employment through such vesting date.